Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Pfizer licenses therapeutic vaccine
April 21, 2008
| A version of this story appeared in
Volume 86, Issue 16
Pfizer has taken an exclusive worldwide license to a therapeutic cancer vaccine being developed by Avant Immunotherapeutics. Under the deal, Pfizer will pay Avant $40 million upfront and make a $10 million investment in the Needham, Mass.-based biotech firm. Avant could receive milestone payments of more than $390 million. The vaccine, CDX-110, is in Phase II development for the treatment of glioblastoma multiforme, an aggressive type of brain tumor. CDX-110 targets a molecule, EGFRvIII, that is expressed in cancer cells but not in normal tissue.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter